|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,535.80 INR | -0.88% |
|
-0.95% | +12.55% |
| Capitalization | 29TCr 319.9Cr 272.65Cr 252.62Cr 237.59Cr 442.24Cr 474.38Cr 2.92TCr 1.15TCr 14TCr 1.2TCr 1.18TCr 51TCr | P/E ratio 2026 * |
30.6x | P/E ratio 2027 * | 25.3x |
|---|---|---|---|---|---|
| Enterprise value | 30TCr 326.88Cr 278.6Cr 258.13Cr 242.77Cr 451.88Cr 484.72Cr 2.98TCr 1.18TCr 14TCr 1.23TCr 1.2TCr 52TCr | EV / Sales 2026 * |
3.3x | EV / Sales 2027 * | 2.87x |
| Free-Float |
13.38% | Yield 2026 * |
0.2% | Yield 2027 * | 0.24% |
Last Transcript: Emcure Pharmaceuticals Limited
| 1 day | -0.88% | ||
| 1 week | -0.95% | ||
| Current month | +12.55% | ||
| 1 month | +10.89% | ||
| 3 months | +11.61% | ||
| 6 months | +12.33% | ||
| Current year | +12.55% |
| 1 week | 1,525.1 |  | 1,585.6 |
| 1 month | 1,356 | | 1,585.6 |
| Current year | 1,388.1 | | 1,585.6 |
| 1 year | 889 | | 1,585.6 |
| 3 years | 889 | | 1,585.6 |
| 5 years | 889 | | 1,585.6 |
| 10 years | 889 | | 1,585.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 75 | 16/04/1981 | |
| Director of Finance/CFO | - | 01/10/2003 | |
Deepak Gondaliya
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | 23/07/2001 | |
| Chairman | 69 | - | |
| Director/Board Member | 75 | 16/04/1981 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.88% | -0.95% | +10.61% | - | 319.9Cr | |
| +0.28% | -3.33% | +43.48% | +200.89% | 93TCr | |
| -0.21% | +2.13% | +48.41% | +29.32% | 53TCr | |
| -0.14% | -3.04% | +24.76% | +43.08% | 38TCr | |
| -0.33% | +0.26% | +27.68% | +16.77% | 37TCr | |
| -1.02% | -6.56% | +21.29% | +21.44% | 28TCr | |
| -0.29% | -1.48% | +27.95% | +33.84% | 28TCr | |
| +0.57% | +1.10% | +11.77% | -0.45% | 27TCr | |
| -1.10% | +1.94% | -32.78% | -20.12% | 27TCr | |
| +0.18% | +2.07% | +21.64% | +25.74% | 18TCr | |
| Average | -0.46% | -0.09% | +20.48% | +38.95% | 34.95TCr | |
| Weighted average by Cap. | -0.12% | -0.40% | +27.94% | +68.65% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 9.03TCr 99Cr 85Cr 78Cr 74Cr 137.1Cr 147.06Cr 903.99Cr 357.14Cr 4.29TCr 371.89Cr 364.27Cr 16TCr | 10TCr 111.64Cr 95Cr 88Cr 83Cr 154.33Cr 165.55Cr 1.02TCr 402.03Cr 4.83TCr 418.65Cr 410.06Cr 18TCr |
| Net income | 942.2Cr 10Cr 8.82Cr 8.18Cr 7.69Cr 14Cr 15Cr 94Cr 37Cr 448.02Cr 39Cr 38Cr 1.63TCr | 1.14TCr 13Cr 11Cr 9.9Cr 9.31Cr 17Cr 19Cr 114.23Cr 45Cr 542.3Cr 47Cr 46Cr 1.98TCr |
| Net Debt | 634.87Cr 6.98Cr 5.95Cr 5.51Cr 5.18Cr 9.64Cr 10Cr 64Cr 25Cr 301.88Cr 26Cr 26Cr 1.1TCr | 3.81Cr 4L 4L 3L 3L 6L 6L 38.19L 15.09L 1.81Cr 15.71L 15.39L 6.62Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/26/20 | 1,535.80 ₹ | -0.88% | 1,94,224 |
| 19/26/19 | 1,549.50 ₹ | -0.58% | 1,68,982 |
| 16/26/16 | 1,558.50 ₹ | -0.77% | 1,72,684 |
| 14/26/14 | 1,570.60 ₹ | +1.29% | 3,10,254 |
| 13/26/13 | 1,550.60 ₹ | +3.44% | 4,80,362 |
End-of-day quote NSE India S.E., January 20, 2026
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- EMCURE Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition